Physician profile
Daniel R Boyce
NPI 1720024797
$2,003.90
in general payments reported to CMS, 2019-2025
33 companies · $50.09 in 2025
The $50.09 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $227 · 2021: $627 · 2022: $209 · 2023: $412 · 2024: $219 · 2025: $50.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $681.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $468.13 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Amgen INC. | $201.61 | 2019-2024 | Otezla, Repatha |
| Abbott Laboratories | $187.34 | 2021-2023 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $133.72 | 2019-2025 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.83 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $110.58 | 2019-2021 | |
| Lilly USA, LLC | $88.49 | 2021-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $84.97 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $73.93 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $60.15 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.27 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.41 | 2019-2021 | |
| Boston Scientific Corporation | $44.44 | 2024 | Watchman Flx |
| Amarin Pharma, INC. | $38.22 | 2019-2021 | |
| Glaxosmithkline, LLC. | $27.10 | 2022-2023 | Shingrix, Trelegy Ellipta, Arexvy |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $22.45 | 2021 | |
| Allergan, INC. | $19.17 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.99 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $17.16 | 2020 | |
| Phathom Pharmaceuticals, INC. | $15.55 | 2024 | Voquezna |
| Dexcom, INC. | $15.14 | 2024 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $14.91 | 2021 | |
| Sumitomo Pharma America, INC. | $13.81 | 2023 | Gemtesa |
| Arbor Pharmaceuticals, INC. | $13.52 | 2021 | |
| Hologic Sales and Service, LLC | $13.32 | 2020 | |
| Shire North American Group INC | $13.31 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.28 | 2024 | |
| Merck Sharp & Dohme LLC | $12.97 | 2022 | |
| Sanofi Pasteur INC. | $12.14 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.00 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.57 | 2019 | |
| Daiichi Sankyo INC. | $11.27 | 2020 | |
| Clarus Therapeutics INC. | $10.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Boyce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.